US health-ingredient company DMC Biotechnologies has raised US$18 million to commercialise KeyPura, its range of bioactives made by precision fermentation, Nutrition Insight reported on 27 October. Inceptional Partners and Sofinnova Partners co-led the financing, with First Bight Ventures joining and existing investors Cibus Capital and Capricorn Partners taking part. DMC did not name the round or disclose a valuation.
At a glance
- US$18M raised; round name and valuation not disclosed
- 2 launch ingredients: myo-inositol and D-chiro-inositol
- 40:1 the myo- to D-chiro-inositol ratio DMC cites from clinical studies in polyendocrine metabolic ovarian syndrome (PMOS, formerly PCOS)
- 3 target markets named: health and wellness, infant nutrition, personal care
Nutrition Insight, 27 October 2026.
What the money is for
DMC says its first KeyPura ingredients are already on the market and that the new capital goes to customer and distribution relationships and to further products. Chief executive Jim Flatt described the next phase as “broader market adoption, new products, and long-term commercial growth”. Andras Forgacs, founder and managing partner of Inceptional Partners, sits on DMC’s board.
The production claim is a feedstock switch. Conventional myo-inositol is made by hydrolysing phytic acid from corn-processing by-products. DMC ferments purified, food-grade dextrose instead, and says the process is more efficient and lower in cost than extraction. It has not published a cost per kilogram, a purity figure against extracted grades or its production capacity.
Where the round sits
The round is larger than the other fermentation-based ingredient raises in recent trade reports. DigitalFoodLab’s 2 November deal list records a US$635K Series A extension for Japan’s IntegriCulture and US$500K for Argentina’s BioClé. Nutrition Insight puts All G’s most recent raise at AU$10 million (US$6.6 million) alongside its lactoferrin partnership with Armor Protéines.
What this means for investors
Investors are paying for a health-ingredient margin here. Inositol already sells as a supplement and infant-nutrition input, so DMC enters with a product buyers know and a cheaper, corn-based incumbent to beat on price. Three numbers decide the case: DMC’s cost per kilogram against extracted myo-inositol, the split of revenue between the two inositols, and whether production runs in DMC’s own tanks or at a contract manufacturer.
Checklist: diligence on a precision-fermented bioactive
Ask for cost per kilogram at current scale beside the spot price of the extracted equivalent.
Split revenue by ingredient; a high-value minor ingredient can carry a commodity one.
Confirm the regulatory status per market, especially for infant nutrition.
Ask who owns the fermentation capacity and on what contract terms.
Sources and reporting
- Nutrition Insight: DMC Biotechnologies raises US$18M to commercialize precision-fermented KeyPura inositols, 27 October 2026
- DigitalFoodLab: 21 FoodTech insights and deals to know this week (2026, week #45), 2 November 2026
Reporting note: Desk report on Nutrition Insight’s 27 October article and DigitalFoodLab’s 2 November deal list. FoodEdge has not spoken to DMC or seen its financials.
AI tools supported source research and drafting during the editorial process.
